• Ublituximab Improves Functional MS Score: New ULTIMATE Analysis

    6 days ago - By Medscape

    The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite score, a measure of disability, compared with teriflunomide.
    Medscape Medical News
    Read more ...

     

  • Novel Anti-CD20 Drug Shows Promise in Relapsing MS

    Novel Anti-CD20 Drug Shows Promise in Relapsing MS

    6 days ago - By MedPageToday

    Ublituximab, an investigational monoclonal antibody targeting CD20, lowered relapse rates relative to teriflunomide in two identical phase III trials of people with relapsing multiple sclerosis .
    At 96 weeks, ublituximab...
    Read more ...